AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

On Monday, a paper announcing that all four DNA bases had been found on an asteroid sparked a lot of headlines. But many of ...

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His had a long list, unfortunately closed by his passing away at the age of 92 ...

In the last few years, Chinese AI startup MiniMax has become one of the most exciting in the crowded global AI marketplace, ...

Genetic signatures help uncover the echoes of the past events in the histories of jewelweed populations, and understand their ...

Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the ...

Investment bank Morgan Stanley has warned that a major breakthrough in artificial intelligence (AI) could arrive in the first half of 2026. This could be driven by a rapid expansion of computing power ...

The AI industry is constantly churning out news, like major acquisitions, indie developer successes, public outcry, and ...

All right. Good morning, again, for I see some familiar face in the last one, but thanks for sticking around. It's good to see everybody, and welcome back to TD Cowen's 46th Annual Healthcare ...

The sweeping correction that most of these stocks have suffered was not only predictable, but it also reliably precedes a better-supported recovery.

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Recursion Pharmaceuticals (RXRX) closed at $3.42 in the latest trading session, marking a -8.06% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.69%.